CL2017003356A1 - Moduladores cot y métodos de uso de los mismos - Google Patents

Moduladores cot y métodos de uso de los mismos

Info

Publication number
CL2017003356A1
CL2017003356A1 CL2017003356A CL2017003356A CL2017003356A1 CL 2017003356 A1 CL2017003356 A1 CL 2017003356A1 CL 2017003356 A CL2017003356 A CL 2017003356A CL 2017003356 A CL2017003356 A CL 2017003356A CL 2017003356 A1 CL2017003356 A1 CL 2017003356A1
Authority
CL
Chile
Prior art keywords
methods
cot
modulators
cot modulators
production
Prior art date
Application number
CL2017003356A
Other languages
English (en)
Inventor
Elizabeth M Bacon
Gayatri Balan
Chien-Hung Chou
Christopher T Clark
Jeromy J Cottell
Musong Kim
Thorsten A Kirschberg
John O Link
Gary Phillips
Scott D Schroeder
Neil H Squires
Kirk L Stevens
James G Taylor
William J Watkins
Nathan E Wright
Sheila M Zipfel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CL2017003356A1 publication Critical patent/CL2017003356A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)

Abstract

<p>LA PRESENTE DIVULGACIÓN SE REFIERE EN GENERAL A MODULADORES DE COT (CÁNCER DE TIROIDES OSAKA) Y MÉTODOS DE USO Y PRODUCCIÓN DE LOS MISMOS.</p>
CL2017003356A 2015-07-06 2017-12-22 Moduladores cot y métodos de uso de los mismos CL2017003356A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189158P 2015-07-06 2015-07-06
US201562269060P 2015-12-17 2015-12-17

Publications (1)

Publication Number Publication Date
CL2017003356A1 true CL2017003356A1 (es) 2018-07-06

Family

ID=56411943

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003356A CL2017003356A1 (es) 2015-07-06 2017-12-22 Moduladores cot y métodos de uso de los mismos

Country Status (41)

Country Link
US (8) US20170008905A1 (es)
EP (4) EP3191470B1 (es)
JP (6) JP6430060B2 (es)
KR (5) KR101974793B1 (es)
CN (4) CN107922390B (es)
AU (5) AU2016290820B2 (es)
BR (1) BR102016015656B1 (es)
CA (1) CA2971640C (es)
CL (1) CL2017003356A1 (es)
CO (1) CO2017013351A2 (es)
CR (1) CR20170599A (es)
CU (1) CU20170172A7 (es)
CY (1) CY1121750T1 (es)
DK (1) DK3191470T3 (es)
DO (1) DOP2017000311A (es)
EA (1) EA036788B1 (es)
EC (1) ECSP17084635A (es)
ES (3) ES2734713T3 (es)
HR (1) HRP20190853T1 (es)
HU (1) HUE043310T2 (es)
IL (4) IL293770B2 (es)
LT (1) LT3191470T (es)
MA (1) MA39422B1 (es)
ME (1) ME03425B (es)
MX (1) MX370984B (es)
MY (1) MY196173A (es)
NZ (2) NZ738525A (es)
PE (1) PE20180462A1 (es)
PH (2) PH12018500031A1 (es)
PL (3) PL3896064T3 (es)
PT (3) PT3896064T (es)
RS (1) RS58639B1 (es)
SA (1) SA517381350B1 (es)
SG (1) SG11201702041PA (es)
SI (3) SI3896064T1 (es)
SM (1) SMT201900244T1 (es)
SV (1) SV2017005605A (es)
TW (3) TWI634112B (es)
UA (1) UA123010C2 (es)
UY (1) UY36771A (es)
WO (1) WO2017007689A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
EP3319955B1 (en) 2015-07-06 2020-11-25 Gilead Sciences, Inc. 6-amino-quinoline-3-carbonitrils as cot modulators
KR101974793B1 (ko) * 2015-07-06 2019-05-02 길리애드 사이언시즈, 인코포레이티드 Cot 조정제 및 그의 사용 방법
EP3478674B1 (en) 2016-06-30 2020-05-13 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
KR20230011471A (ko) * 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
EP3689866A4 (en) * 2017-09-26 2021-07-07 Nippon Soda Co., Ltd. QUINOLINE COMPOUND AND BACTERICIDAL AGENT FOR AGRICULTURE AND HORTICULTURE
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
WO2019161280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110294660B (zh) * 2018-03-23 2021-09-24 中国农业大学 一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法
CN108658996A (zh) * 2018-06-25 2018-10-16 中国药科大学 一种氘代Fiduxosin的制备方法
CN120053445A (zh) 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
EP4010348B1 (en) 2019-08-09 2023-12-20 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
JP7604457B2 (ja) 2019-08-15 2024-12-23 イドルシア・ファーマシューティカルズ・リミテッド ２－ヒドロキシシクロアルカン－１－カルバモイル誘導体
CA3148365A1 (en) 2019-08-29 2021-03-04 Martin Bolli Alpha-d-galactopyranoside derivatives
TWI854067B (zh) 2019-11-26 2024-09-01 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
AU2021249010B2 (en) 2020-03-30 2024-09-26 Gilead Sciences, Inc. Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
JP7446475B2 (ja) * 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔ阻害剤化合物を調製するためのプロセス
PL4172157T3 (pl) 2020-06-25 2026-03-23 Gilead Sciences, Inc. Inhibitory kapsydu w leczeniu hiv
ES3014851T3 (en) 2020-10-06 2025-04-25 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
KR20230104190A (ko) 2020-11-02 2023-07-07 이도르시아 파마슈티컬스 리미티드 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
KR20230145111A (ko) 2021-02-09 2023-10-17 이도르시아 파마슈티컬스 리미티드 히드록시헤테로시클로알칸-카르바모일 유도체
PL4301748T3 (pl) 2021-03-03 2025-09-08 Idorsia Pharmaceuticals Ltd Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu
TW202304435A (zh) * 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
AU2022289728A1 (en) * 2021-06-11 2023-11-16 Neuronascent, Inc. Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
DK4445900T3 (da) 2021-12-03 2025-08-18 Gilead Sciences Inc Terapeutiske forbindelser til hiv-virusinfektion
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
WO2024245157A1 (zh) * 2023-05-30 2024-12-05 浙江星浩澎博医药有限公司 氮杂喹啉环衍生物
WO2024249983A1 (en) * 2023-06-02 2024-12-05 Westol, Llc 2,8-dihydroxyquinoline glucuronide derivatives with enhanced properties for use as anticancer, antiviral, antimicrobial, and other therapeutic applications
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
KR102732584B1 (ko) 2024-03-28 2024-11-21 (주)신한티이씨 전기 배전반의 화재 위험 감지 및 진압용 소화 장치

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930837A (en) 1971-12-31 1976-01-06 Ici Australia Limited 3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
NL7800191A (nl) 1977-01-10 1978-07-12 Ciba Geigy Anthelmintisch preparaat.
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja) 1988-07-26 1997-07-23 三井東圧化学株式会社 不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
GB9310700D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Novel composition
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
AU734678B2 (en) 1997-08-28 2001-06-21 Nissan Chemical Industries Ltd. Industrial antibacterial and antifungal agents, algicides and agents for preventing adhesion of organisms containing a cyanoacrylate compound
EP1097158B1 (en) 1998-07-10 2006-01-25 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
BR9914164A (pt) 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
HRP20040853A2 (en) 2002-03-20 2004-12-31 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
PL378754A1 (pl) 2003-03-03 2006-05-15 F.Hoffmann-La Roche Ag 2,5- i 2,6-Podstawione tetrahydroizochinoliny do stosowania jako modulatory 5-HT6
AU2004267061A1 (en) 2003-08-19 2005-03-03 Wyeth Holdings Corporation Process for the preparation of 4-amino-3-quinolinecarbonitriles
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) * 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006124944A1 (en) 2005-05-18 2006-11-23 Wyeth 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
BRPI0609928A2 (pt) 2005-05-18 2010-05-11 Wyeth Corp inibidores de quinase tpl-2 de 3-cianoquinolina e métodos de fabricação e uso dos mesmos
TW200819441A (en) 2005-10-28 2008-05-01 Abbott Lab Prodrugs of compounds that inhibit TRPV1 receptor
JP5255559B2 (ja) 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
JP5599614B2 (ja) 2006-11-09 2014-10-01 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
WO2008092292A1 (en) 2007-01-17 2008-08-07 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2
GB0820856D0 (en) 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) * 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
EP2581372B1 (en) 2010-06-09 2017-06-07 Tianjin Hemay Oncology Pharmaceutical Co., Ltd. Cyanoquinoline derivatives
JP6110787B2 (ja) 2011-05-10 2017-04-05 協和発酵キリン株式会社 ピリミドジアゼピノン化合物
EP2729007A1 (de) 2011-07-04 2014-05-14 Bayer Intellectual Property GmbH Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
PL2772482T3 (pl) 2011-10-27 2016-08-31 Taisho Pharmaceutical Co Ltd Pochodna azolu
LT2776038T (lt) 2011-11-11 2018-04-25 Gilead Apollo, Llc Acc inhibitoriai ir jų panaudojimas
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh) 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
CN103408572B (zh) 2013-07-12 2015-12-02 上海工程技术大学 手性氨基硼酸衍生物及其制备方法和应用
CN108947867A (zh) 2013-12-12 2018-12-07 卡利拉制药公司 双环烷基化合物及合成
CA2942144C (en) 2014-03-07 2023-08-22 Kalyra Pharmaceuticals, Inc. Propellane derivates and synthesis
WO2016007966A2 (en) * 2014-07-11 2016-01-14 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
CN106999451B (zh) 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
EP3197448B1 (en) 2014-09-24 2019-04-24 Gilead Sciences, Inc. Methods of treating liver disease
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
TWI685491B (zh) 2014-12-23 2020-02-21 美商基利科學股份有限公司 製備５-（４-環丙基-１ｈ-咪唑-１-基）-ｎ-（６-（４-異丙基-４ｈ-１,２,４-三唑-３-基）吡啶-２-基）-２-氟-４-甲基苯甲醯胺之方法
JP2018501276A (ja) 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
KR102205143B1 (ko) 2015-01-16 2021-01-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 그리드 결과를 개선하기 위해 그리드 액션을 선택하기 위한 시스템 및 방법
KR101974793B1 (ko) 2015-07-06 2019-05-02 길리애드 사이언시즈, 인코포레이티드 Cot 조정제 및 그의 사용 방법
EP3319955B1 (en) * 2015-07-06 2020-11-25 Gilead Sciences, Inc. 6-amino-quinoline-3-carbonitrils as cot modulators
ES2920888T3 (es) 2015-12-31 2022-08-11 Hitgen Inc Derivado de sulfonamida y método de preparación y uso del mismo
CN119977993A (zh) 2016-03-02 2025-05-13 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
EP3473715B1 (en) 2016-06-21 2021-08-04 PHC Holdings Corporation Catalase inhibitor and method for measuring analyte using catalase inhibitor
EP3478674B1 (en) 2016-06-30 2020-05-13 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
CN106512014A (zh) 2016-10-27 2017-03-22 武汉大学 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
EP4273132A3 (en) 2017-03-03 2024-01-10 Gilead Sciences, Inc. Processes for preparing acc inhibitors and solid forms thereof
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
AU2018250614A1 (en) 2017-04-12 2019-10-17 Gilead Sciences, Inc. Methods of treating liver disease
KR102419458B1 (ko) 2017-10-06 2022-07-12 길리애드 사이언시즈, 인코포레이티드 Acc 억제제를 포함하는 조합 요법
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
WO2020185685A1 (en) 2019-03-08 2020-09-17 The Regents Of The University Of California Compositions and methods for treating acne
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
AU2021249010B2 (en) 2020-03-30 2024-09-26 Gilead Sciences, Inc. Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
JP7446475B2 (ja) 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔ阻害剤化合物を調製するためのプロセス
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法

Also Published As

Publication number Publication date
PL3191470T3 (pl) 2019-08-30
AU2022204050A1 (en) 2022-06-30
CO2017013351A2 (es) 2018-05-21
IL293770B2 (en) 2023-07-01
SI3896064T1 (sl) 2025-07-31
TW201712005A (zh) 2017-04-01
UA123010C2 (uk) 2021-02-03
IL274568A (en) 2020-06-30
CR20170599A (es) 2018-02-28
AU2024204902A1 (en) 2024-08-01
AU2019203122B2 (en) 2020-10-01
CN109879859A (zh) 2019-06-14
JP6781221B2 (ja) 2020-11-04
EP3456717B1 (en) 2021-03-17
US20230002407A1 (en) 2023-01-05
JP2018193405A (ja) 2018-12-06
AU2019203122A1 (en) 2019-05-30
US20190248807A1 (en) 2019-08-15
US20170008905A1 (en) 2017-01-12
SG11201702041PA (en) 2017-04-27
EP3191470A1 (en) 2017-07-19
US11066414B2 (en) 2021-07-20
KR102073641B1 (ko) 2020-02-05
CA2971640C (en) 2020-09-22
EA201792613A1 (ru) 2018-06-29
ME03425B (me) 2020-01-20
JP6430060B2 (ja) 2018-11-28
JP2019178178A (ja) 2019-10-17
IL256433A (en) 2018-02-28
CN119143730A (zh) 2024-12-17
SA517381350B1 (ar) 2021-03-11
ES3034100T3 (en) 2025-08-13
US11905299B2 (en) 2024-02-20
AU2016290820A1 (en) 2018-01-18
EA036788B1 (ru) 2020-12-21
EP3896064B1 (en) 2025-05-21
KR20200013120A (ko) 2020-02-05
KR102443575B1 (ko) 2022-09-16
PH12018500031B1 (en) 2018-07-09
CN107922390A (zh) 2018-04-17
IL293770B1 (en) 2023-03-01
KR20240008398A (ko) 2024-01-18
NZ738525A (en) 2019-03-29
PH12020551397A1 (en) 2021-08-16
KR20180022982A (ko) 2018-03-06
BR102016015656A2 (pt) 2020-09-24
PT3191470T (pt) 2019-06-05
JP6906021B2 (ja) 2021-07-21
AU2022204050B2 (en) 2024-04-18
HRP20190853T1 (hr) 2019-06-28
EP3456717A1 (en) 2019-03-20
IL274568B (en) 2022-07-01
KR101974793B1 (ko) 2019-05-02
SMT201900244T1 (it) 2019-05-10
PL3896064T3 (pl) 2025-09-08
WO2017007689A1 (en) 2017-01-12
JP2021042252A (ja) 2021-03-18
EP3191470B1 (en) 2019-02-27
BR102016015656B1 (pt) 2021-11-03
US20180237455A1 (en) 2018-08-23
ES2872076T3 (es) 2021-11-02
SV2017005605A (es) 2018-07-18
CN114380799B (zh) 2024-10-01
CN114380799A (zh) 2022-04-22
PE20180462A1 (es) 2018-03-06
PT3896064T (pt) 2025-07-03
AU2016290820B2 (en) 2019-03-07
TWI748539B (zh) 2021-12-01
IL266995B (en) 2020-05-31
KR20190045416A (ko) 2019-05-02
MX370984B (es) 2020-01-09
KR20220129667A (ko) 2022-09-23
US9878995B2 (en) 2018-01-30
EP4613332A2 (en) 2025-09-10
ES2734713T3 (es) 2019-12-11
US20240254137A1 (en) 2024-08-01
SI3191470T1 (sl) 2019-04-30
TWI634112B (zh) 2018-09-01
JP2024100865A (ja) 2024-07-26
UY36771A (es) 2017-01-31
JP2022082816A (ja) 2022-06-02
AU2020257055B2 (en) 2022-03-31
TW201908305A (zh) 2019-03-01
SI3456717T1 (sl) 2021-08-31
US20200123172A1 (en) 2020-04-23
RS58639B1 (sr) 2019-05-31
MY196173A (en) 2023-03-17
CN109879859B (zh) 2022-01-25
CN107922390B (zh) 2019-05-10
DOP2017000311A (es) 2018-01-15
CY1121750T1 (el) 2020-07-31
AU2020257055A1 (en) 2020-11-12
TW202114673A (zh) 2021-04-16
US20170152240A1 (en) 2017-06-01
ECSP17084635A (es) 2018-01-31
MA39422B1 (fr) 2019-03-29
NZ750707A (en) 2023-09-29
US20250346609A1 (en) 2025-11-13
HUE043310T2 (hu) 2019-08-28
JP7138155B2 (ja) 2022-09-15
PH12018500031A1 (en) 2018-07-09
DK3191470T3 (en) 2019-04-15
MA39422A (fr) 2017-07-19
LT3191470T (lt) 2019-05-10
TWI699361B (zh) 2020-07-21
PT3456717T (pt) 2021-05-26
CU20170172A7 (es) 2018-06-05
EP3896064A1 (en) 2021-10-20
EP4613332A3 (en) 2025-12-10
IL256433B (en) 2019-06-30
CA2971640A1 (en) 2017-01-12
IL293770A (en) 2022-08-01
IL266995A (en) 2019-07-31
PL3456717T3 (pl) 2021-10-25
JP2018520161A (ja) 2018-07-26
MX2017004737A (es) 2017-06-19

Similar Documents

Publication Publication Date Title
CL2017003356A1 (es) Moduladores cot y métodos de uso de los mismos
CL2023001911A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX388018B (es) Anticuerpos anti-pd1 y métodos de uso.
CL2019002824A1 (es) Anticuerpos anti-lag3.
ECSP18007905A (es) Anticuerpos monoclonales contra bcma
CL2016002455A1 (es) Anticuerpos multiespecíficos.
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
MX2015017341A (es) Anticuerpos anti-factor del complemento c1q y uso de los mismos.
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
MX2016005631A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
MX2015015220A (es) Compuestos conjugados antisentido y su uso.
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
DOP2023000172A (es) Moduladores de cot y métodos de uso de los mismos
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
AR121189A2 (es) Anticuerpos anti-tigit y métodos de uso
EA202092495A1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ